Soligenix (SNGX) Assets Average (2011 - 2026)
Soligenix's (SNGX) quarterly Assets Average came in at $8.1 million in Q1 2026, down 3.32% YoY from $8.4 million in Q1 2025, and down 21.29% on a QoQ basis from $10.3 million in Q4 2025.
Soligenix (SNGX) Assets Average (2011 - 2026) Analysis & Trends
Soligenix (SNGX) has 16 years of Assets Average data on file, last reported at $8.1 million in Q1 2026.
- Quarterly Assets Average fell 3.32% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.1 million (down 3.32% YoY) and the FY2025 annual result came in at $9.1 million, down 2.99% from the prior year.
- Assets Average eased to $8.1 million in Q1 2026, from $10.3 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $25.3 million in Q1 2022 to a low of $6.8 million in Q2 2025.
- A 5-year average of $12.4 million and a median of $10.3 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average slumped 49.78% — and 2025, when it grew 5.59%.
- Tracing SNGX's Assets Average over 5 years: stood at $16.1 million in 2022, then plunged by 34.53% to $10.6 million in 2023, then retreated by 7.85% to $9.7 million in 2024, then climbed by 5.59% to $10.3 million in 2025, then declined by 21.29% to $8.1 million in 2026.
- The last three Assets Average figures came in at $8.1 million (Q1 2026), $10.3 million (Q4 2025), and $8.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | 8.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.71 Mn |
| Mar 31, 2026 | 8.08 Mn |
| Dec 31, 2025 | 10.26 Mn |
| Sep 30, 2025 | 8.53 Mn |
| Jun 30, 2025 | 6.75 Mn |
| Mar 31, 2025 | 8.36 Mn |
| Dec 31, 2024 | 9.72 Mn |
| Sep 30, 2024 | 10.17 Mn |
| Jun 30, 2024 | 8.96 Mn |
| Mar 31, 2024 | 8.93 Mn |
| Dec 31, 2023 | 10.55 Mn |
| Sep 30, 2023 | 12.56 Mn |
| Jun 30, 2023 | 12.46 Mn |
| Mar 31, 2023 | 12.69 Mn |
| Dec 31, 2022 | 16.11 Mn |
| Sep 30, 2022 | 19.63 Mn |
| Jun 30, 2022 | 22.49 Mn |
| Mar 31, 2022 | 25.27 Mn |
| Dec 31, 2021 | 28.29 Mn |
| Sep 30, 2021 | 29.66 Mn |